Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

P. M. Fracasso, K. A. Blum, M. K. Ma, B. R. Tan, L. P. Wright, S. A. Goodner, C. L. Fears, W. Hou, M. A. Arquette, J. Picus, Alex Denes, J. E. Mortimer, L. Ratner, S. P. Ivy, H. L. McLeod

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in doxorubicin dose reduction. In animal models, valspodar has minimal interaction with pegylated liposomal doxorubicin (PEG-LD). To determine any pharmacokinetic interaction in humans, we designed a study to determine maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of total doxorubicin, in PEG-LD and valspodar combination therapy in patients with advanced malignancies. Patients received PEG-LD 20-25 mg m-2 intravenously over 1 h for cycle one. In subsequent 2-week cycles, valspodar was administered as 72 h continuous intravenous infusion with PEG-LD beginning at 8 mg m-2 and escalated in an accelerated titration design to 25 mg m-2. Pharmacokinetic data were collected with and without valspodar. A total of 14 patients completed at least two cycles of therapy. No DLTs were observed in six patients treated at the highest level of PEG-LD 25 mg m-2. The most common toxicities were fatigue, nausea, vomiting, mucositis, palmar plantar erythrodysesthesia, diarrhoea, and ataxia. Partial responses were observed in patients with breast and ovarian carcinoma. The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h-1 m-2 in cycle 1 to 18 (3-37) ml h-1 m-2 with the addition of valspodar in cycle 2 (P = 0.009). Treatment with PEG-LD 25 mg m-2 in combination with valspodar results in a moderate prolongation of total doxorubicin clearance and half-life but did not increase the toxicity of this agent.

Original languageEnglish (US)
Pages (from-to)46-53
Number of pages8
JournalBritish Journal of Cancer
Volume93
Issue number1
DOIs
StatePublished - Jul 11 2005
Externally publishedYes

Fingerprint

Multiple Drug Resistance
Doxorubicin
Pharmacokinetics
Mucositis
Maximum Tolerated Dose
P-Glycoprotein
Ataxia
liposomal doxorubicin
valspodar
Intravenous Infusions
Nausea
Vomiting
Fatigue
Half-Life
Diarrhea
Therapeutics
Animal Models
Breast Neoplasms
Neoplasms

Keywords

  • Doxil
  • Multidrug resistance
  • Pegylated liposomal doxorubicin
  • PSC 833
  • Valspodar

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fracasso, P. M., Blum, K. A., Ma, M. K., Tan, B. R., Wright, L. P., Goodner, S. A., ... McLeod, H. L. (2005). Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. British Journal of Cancer, 93(1), 46-53. https://doi.org/10.1038/sj.bjc.6602653

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. / Fracasso, P. M.; Blum, K. A.; Ma, M. K.; Tan, B. R.; Wright, L. P.; Goodner, S. A.; Fears, C. L.; Hou, W.; Arquette, M. A.; Picus, J.; Denes, Alex; Mortimer, J. E.; Ratner, L.; Ivy, S. P.; McLeod, H. L.

In: British Journal of Cancer, Vol. 93, No. 1, 11.07.2005, p. 46-53.

Research output: Contribution to journalArticle

Fracasso, PM, Blum, KA, Ma, MK, Tan, BR, Wright, LP, Goodner, SA, Fears, CL, Hou, W, Arquette, MA, Picus, J, Denes, A, Mortimer, JE, Ratner, L, Ivy, SP & McLeod, HL 2005, 'Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar', British Journal of Cancer, vol. 93, no. 1, pp. 46-53. https://doi.org/10.1038/sj.bjc.6602653
Fracasso, P. M. ; Blum, K. A. ; Ma, M. K. ; Tan, B. R. ; Wright, L. P. ; Goodner, S. A. ; Fears, C. L. ; Hou, W. ; Arquette, M. A. ; Picus, J. ; Denes, Alex ; Mortimer, J. E. ; Ratner, L. ; Ivy, S. P. ; McLeod, H. L. / Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. In: British Journal of Cancer. 2005 ; Vol. 93, No. 1. pp. 46-53.
@article{f2bbd81ce5ba437786bdd1d6faf2acd5,
title = "Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar",
abstract = "Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in doxorubicin dose reduction. In animal models, valspodar has minimal interaction with pegylated liposomal doxorubicin (PEG-LD). To determine any pharmacokinetic interaction in humans, we designed a study to determine maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of total doxorubicin, in PEG-LD and valspodar combination therapy in patients with advanced malignancies. Patients received PEG-LD 20-25 mg m-2 intravenously over 1 h for cycle one. In subsequent 2-week cycles, valspodar was administered as 72 h continuous intravenous infusion with PEG-LD beginning at 8 mg m-2 and escalated in an accelerated titration design to 25 mg m-2. Pharmacokinetic data were collected with and without valspodar. A total of 14 patients completed at least two cycles of therapy. No DLTs were observed in six patients treated at the highest level of PEG-LD 25 mg m-2. The most common toxicities were fatigue, nausea, vomiting, mucositis, palmar plantar erythrodysesthesia, diarrhoea, and ataxia. Partial responses were observed in patients with breast and ovarian carcinoma. The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h-1 m-2 in cycle 1 to 18 (3-37) ml h-1 m-2 with the addition of valspodar in cycle 2 (P = 0.009). Treatment with PEG-LD 25 mg m-2 in combination with valspodar results in a moderate prolongation of total doxorubicin clearance and half-life but did not increase the toxicity of this agent.",
keywords = "Doxil, Multidrug resistance, Pegylated liposomal doxorubicin, PSC 833, Valspodar",
author = "Fracasso, {P. M.} and Blum, {K. A.} and Ma, {M. K.} and Tan, {B. R.} and Wright, {L. P.} and Goodner, {S. A.} and Fears, {C. L.} and W. Hou and Arquette, {M. A.} and J. Picus and Alex Denes and Mortimer, {J. E.} and L. Ratner and Ivy, {S. P.} and McLeod, {H. L.}",
year = "2005",
month = "7",
day = "11",
doi = "10.1038/sj.bjc.6602653",
language = "English (US)",
volume = "93",
pages = "46--53",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

AU - Fracasso, P. M.

AU - Blum, K. A.

AU - Ma, M. K.

AU - Tan, B. R.

AU - Wright, L. P.

AU - Goodner, S. A.

AU - Fears, C. L.

AU - Hou, W.

AU - Arquette, M. A.

AU - Picus, J.

AU - Denes, Alex

AU - Mortimer, J. E.

AU - Ratner, L.

AU - Ivy, S. P.

AU - McLeod, H. L.

PY - 2005/7/11

Y1 - 2005/7/11

N2 - Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in doxorubicin dose reduction. In animal models, valspodar has minimal interaction with pegylated liposomal doxorubicin (PEG-LD). To determine any pharmacokinetic interaction in humans, we designed a study to determine maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of total doxorubicin, in PEG-LD and valspodar combination therapy in patients with advanced malignancies. Patients received PEG-LD 20-25 mg m-2 intravenously over 1 h for cycle one. In subsequent 2-week cycles, valspodar was administered as 72 h continuous intravenous infusion with PEG-LD beginning at 8 mg m-2 and escalated in an accelerated titration design to 25 mg m-2. Pharmacokinetic data were collected with and without valspodar. A total of 14 patients completed at least two cycles of therapy. No DLTs were observed in six patients treated at the highest level of PEG-LD 25 mg m-2. The most common toxicities were fatigue, nausea, vomiting, mucositis, palmar plantar erythrodysesthesia, diarrhoea, and ataxia. Partial responses were observed in patients with breast and ovarian carcinoma. The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h-1 m-2 in cycle 1 to 18 (3-37) ml h-1 m-2 with the addition of valspodar in cycle 2 (P = 0.009). Treatment with PEG-LD 25 mg m-2 in combination with valspodar results in a moderate prolongation of total doxorubicin clearance and half-life but did not increase the toxicity of this agent.

AB - Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in doxorubicin dose reduction. In animal models, valspodar has minimal interaction with pegylated liposomal doxorubicin (PEG-LD). To determine any pharmacokinetic interaction in humans, we designed a study to determine maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of total doxorubicin, in PEG-LD and valspodar combination therapy in patients with advanced malignancies. Patients received PEG-LD 20-25 mg m-2 intravenously over 1 h for cycle one. In subsequent 2-week cycles, valspodar was administered as 72 h continuous intravenous infusion with PEG-LD beginning at 8 mg m-2 and escalated in an accelerated titration design to 25 mg m-2. Pharmacokinetic data were collected with and without valspodar. A total of 14 patients completed at least two cycles of therapy. No DLTs were observed in six patients treated at the highest level of PEG-LD 25 mg m-2. The most common toxicities were fatigue, nausea, vomiting, mucositis, palmar plantar erythrodysesthesia, diarrhoea, and ataxia. Partial responses were observed in patients with breast and ovarian carcinoma. The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h-1 m-2 in cycle 1 to 18 (3-37) ml h-1 m-2 with the addition of valspodar in cycle 2 (P = 0.009). Treatment with PEG-LD 25 mg m-2 in combination with valspodar results in a moderate prolongation of total doxorubicin clearance and half-life but did not increase the toxicity of this agent.

KW - Doxil

KW - Multidrug resistance

KW - Pegylated liposomal doxorubicin

KW - PSC 833

KW - Valspodar

UR - http://www.scopus.com/inward/record.url?scp=23044500423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044500423&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602653

DO - 10.1038/sj.bjc.6602653

M3 - Article

C2 - 15942626

AN - SCOPUS:23044500423

VL - 93

SP - 46

EP - 53

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -